Viridian Therapeutics, Inc.\DE
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 221 CRESCENT STREET, WALTHAM, MA, 02453
Mailing Address 221 CRESCENT STREET, WALTHAM, MA, 02453
Phone 617.272.4600
Fiscal Year End 1231
EIN 471187261
Financial Overview
FY2024
-$269.95M
Net Income
$48.40M
Total Liabilities
$442.02M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| 4 Insider stock transaction report | January 2, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 5, 2025 | View on SEC |
| 8-K Current report of material events | November 5, 2025 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | October 27, 2025 | View on SEC |
| 4 Insider stock transaction report | October 27, 2025 | View on SEC |
| 424B5 Prospectus supplement | October 23, 2025 | View on SEC |
| 8-K Current report of material events | October 23, 2025 | View on SEC |
| 424B5 Prospectus supplement | October 21, 2025 | View on SEC |
Insider Trading
SELL 1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.